{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:49:11Z","timestamp":1768808951866,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite declining mortality in most countries and in Lithuania, ovarian cancer burden has remained high. Studies have indicated that antihypertensive medications use may help to improve ovarian cancer survival, however findings remain controversial. The aim of the study was to analyse the association between post-diagnosis antihypertensive medications intake and cancer-specific survival in ovarian cancer patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study included 588 ovarian cancer cases diagnosed between 2013 and 2015. Hazard ratios (HR) and corresponding 95% confidence intervals (95%CI) were estimated using multivariable Cox proportional hazards models to assess associations between antihypertensive medications and ovarian cancer-specific mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 279 (47%) patients died during the follow-up; 242 (87%) of them died due to ovarian cancer. The risk of ovarian cancer death was reduced in angiotensin-converting enzyme inhibitors (ACE inhibitors) users vs. non-users (HR 0.55, 95% CI: 0.36\u20130.83). Subgroup analysis showed better ovarian cancer survival in higher dose ACE inhibitors users (HR 0.46, 95% CI: 0.28\u20130.77, p for trend 0.002); the effect was also stronger in age 51\u201365 years, stage I\u2013III, surgery or chemotherapy treatment, pre-diagnosis ACE inhibitor users\u2019 and pre-diagnosis hypertension subgroups. The risk of cancer-specific death was slightly lower among calcium-channel blocker and angiotensin-receptor blocker users and higher among beta-blocker users as compared to non-users, however chance and confounding could not be ruled out. We found no association between the use of centrally and peripherally acting antiadrenergic agents and diuretics and risk of ovarian cancer-specific mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings imply that post-diagnosis use of ACE inhibitors may be associated with reduced ovarian cancer-specific mortality; however, further research is needed for the comprehensive assessment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-024-02983-7","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T15:01:46Z","timestamp":1709564506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of antihypertensive medications use and survival in patients with ovarian cancer: a population-based retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4887-8894","authenticated-orcid":false,"given":"R\u016bta","family":"Everatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Kuzmickien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birut\u0117","family":"Brasi\u016bnien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ieva","family":"Vincer\u017eevskien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birut\u0117","family":"Intait\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saulius","family":"Cic\u0117nas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrida","family":"Lisauskien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"2983_CR1","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2020. Available from: https:\/\/gco.iarc.fr\/today. Accessed 28 February 2023."},{"issue":"7","key":"2983_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/medicina56070347","volume":"56","author":"R Everatt","year":"2020","unstructured":"Everatt R, Intait\u0117 B. Trends in Mortality Rates of Corpus Uteri and Ovarian Cancer in Lithuania, 1987\u20132016. Med (Kaunas). 2020;56(7):347. https:\/\/doi.org\/10.3390\/medicina56070347.","journal-title":"Med (Kaunas)"},{"key":"2983_CR3","unstructured":"WCRF\/AICR. Continuous Update Project Report. Diet, nutrition, physical activity and colorectal cancer. 2017. Washington (DC): American Institute for Cancer Research. https:\/\/www.wcrf.org\/diet-activity-and-cancer\/cancer-types\/ovarian-cancer\/. Accessed 06 June 2023."},{"issue":"8","key":"2983_CR4","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, International Agency for Research on Cancer Handbook Working Group. Body fatness and Cancer\u2013viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794\u20138. https:\/\/doi.org\/10.1056\/NEJMsr1606602.","journal-title":"N Engl J Med"},{"issue":"8","key":"2983_CR5","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/ijc.29207","volume":"136","author":"D Aune","year":"2015","unstructured":"Aune D, Navarro Rosenblatt DA, Chan DS, Abar L, Vingeliene S, Vieira AR, et al. Anthropometric factors and ovarian cancer risk: a systematic review and nonlinear dose-response meta-analysis of prospective studies. Int J Cancer. 2015;136(8):1888\u201398. https:\/\/doi.org\/10.1002\/ijc.29207.","journal-title":"Int J Cancer"},{"issue":"9","key":"2983_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/cancers13092087","volume":"13","author":"EEE Santala","year":"2021","unstructured":"Santala EEE, Artama M, Pukkala E, Visvanathan K, Staff S, Murtola TJ. Antihypertensive Drug Use and the risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients-A Nationwide Cohort Study. Cancers (Basel). 2021;13(9):2087. https:\/\/doi.org\/10.3390\/cancers13092087.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2983_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ygyno.2021.09.009","volume":"63","author":"T Huang","year":"2021","unstructured":"Huang T, Townsend MK, Dood RL, Sood AK, Tworoger SS. Antihypertensive medication use and ovarian cancer survival. Gynecol Oncol. 2021;63(2):342\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2021.09.009.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2983_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ygyno.2019.05.030","volume":"154","author":"BN Harding","year":"2019","unstructured":"Harding BN, Delaney JA, Urban RR, Weiss NS. Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer. Gynecol Oncol. 2019;154(2):426\u201331. https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.030.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2983_CR9","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4143\/crt.2019.509","volume":"52","author":"MA Cho","year":"2020","unstructured":"Cho MA, Jeong SY, Sohn I, Kim MS, Kang JH, Paik ES, et al. Impact of angiotensin receptor blockers, Beta blockers, Calcium Channel Blockers and Thiazide diuretics on Survival of Ovarian Cancer patients. Cancer Res Treat. 2020;52(2):645\u201354. https:\/\/doi.org\/10.4143\/crt.2019.509.","journal-title":"Cancer Res Treat"},{"issue":"19","key":"2983_CR10","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1002\/cncr.29392","volume":"121","author":"JL Watkins","year":"2015","unstructured":"Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015;121(19):3444\u201351. https:\/\/doi.org\/10.1002\/cncr.29392.","journal-title":"Cancer"},{"issue":"2","key":"2983_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.22.00097","volume":"41","author":"K Spilsbury","year":"2023","unstructured":"Spilsbury K, Tuesley KM, Pearson SA, Coory MD, Donovan P, Steer CB, et al. Perioperative Beta-Blocker Supply and Survival in Women with epithelial ovarian Cancer and a history of Cardiovascular conditions. J Clin Oncol. 2023;41(2):266\u201375. https:\/\/doi.org\/10.1200\/JCO.22.00097.","journal-title":"J Clin Oncol"},{"key":"2983_CR12","doi-asserted-by":"publisher","first-page":"665617","DOI":"10.3389\/fonc.2021.665617","volume":"11","author":"ZY Wen","year":"2021","unstructured":"Wen ZY, Gao S, Gong TT, Jiang YT, Zhang JY, Zhao YH, et al. Post-diagnostic Beta blocker use and prognosis of ovarian Cancer: a systematic review and Meta-analysis of 11 Cohort Studies with 20,274 patients. Front Oncol. 2021;11:665617. https:\/\/doi.org\/10.3389\/fonc.2021.665617.","journal-title":"Front Oncol"},{"issue":"3","key":"2983_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.ygyno.2020.03.012","volume":"157","author":"R Gonzalez","year":"2020","unstructured":"Gonzalez R, Gockley AA, Melamed A, Sugrue R, Clark RM, Del Carmen MG, et al. Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer. Gynecol Oncol. 2020;157(3):700\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2020.03.012.","journal-title":"Gynecol Oncol"},{"key":"2983_CR14","doi-asserted-by":"publisher","first-page":"101579","DOI":"10.1016\/j.canep.2019.101579","volume":"62","author":"A Couttenier","year":"2019","unstructured":"Couttenier A, Lacroix O, Silversmit G, Vaes E, De Schutter H, Robert A. Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study. Cancer Epidemiol. 2019;62:101579. https:\/\/doi.org\/10.1016\/j.canep.2019.101579.","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"2983_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ygyno.2021.05.021","volume":"162","author":"GE Hanley","year":"2021","unstructured":"Hanley GE, Kaur P, Berchuck A, Chase A, Grout B, Deurloo CM, et al. Cardiovascular medications and survival in people with ovarian cancer: a population-based cohort study from British Columbia, Canada. Gynecol Oncol. 2021;162(2):461\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2021.05.021.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2983_CR16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ygyno.2020.03.028","volume":"157","author":"A Majidi","year":"2020","unstructured":"Majidi A, Na R, Dixon-Suen S, Jordan SJ, Webb PM. Common medications and survival in women with ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2020;157(3):678\u201385. https:\/\/doi.org\/10.1016\/j.ygyno.2020.03.028.","journal-title":"Gynecol Oncol"},{"key":"2983_CR17","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s10654-021-00802-z","volume":"36","author":"S M\u00f6ller","year":"2021","unstructured":"M\u00f6ller S, Bliddal M, Rubin KH. Methodical considerations on adjusting for Charlson Comorbidity Index in epidemiological studies. Eur J Epidemiol. 2021;36:1123\u201328. https:\/\/doi.org\/10.1007\/s10654-021-00802-z.","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"2983_CR18","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/ijc.33333","volume":"148","author":"A Majidi","year":"2021","unstructured":"Majidi A, Na R, Jordan SJ, De Fazio A, Webb PM, OPAL Study Group. Statin use and survival following a diagnosis of ovarian cancer: a prospective observational study. Int J Cancer. 2021;148(7):1608\u201315. https:\/\/doi.org\/10.1002\/ijc.33333.","journal-title":"Int J Cancer"},{"key":"2983_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1186\/s12885-018-4676-z","volume":"18","author":"E Urpilainen","year":"2018","unstructured":"Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, et al. Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study. BMC Cancer. 2018;18:767. https:\/\/doi.org\/10.1186\/s12885-018-4676-z.","journal-title":"BMC Cancer"},{"issue":"4","key":"2983_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.medici.2017.07.004","volume":"53","author":"I Lisauskien\u0117","year":"2017","unstructured":"Lisauskien\u0117 I, Garuolien\u0117 K, Gulbinovi\u010d J. Utilization of cardiovascular medicines and cardiovascular mortality in Lithuania, Sweden and Norway in 2003\u20132012. Med (Kaunas). 2017;53(4):259\u201367. https:\/\/doi.org\/10.1016\/j.medici.2017.07.004.","journal-title":"Med (Kaunas)"},{"key":"2983_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-211-89836-9_368","volume-title":"Dictionary of Pharmaceutical Medicine","author":"G Nahler","year":"2009","unstructured":"Nahler G. Defined daily dose (DDD). Dictionary of Pharmaceutical Medicine. Viena: Springer Vienna; 2009. https:\/\/doi.org\/10.1007\/978-3-211-89836-9_368."},{"key":"2983_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2016.04.004","volume":"47","author":"J Weberpals","year":"2016","unstructured":"Weberpals J, Jansen L, Carr PR, Hoffmeister M, Brenner H. Beta blockers and cancer prognosis \u2013 the role of immortal time bias: a systematic review and meta-analysis. Cancer Treat Rev. 2016;47:1\u201311. https:\/\/doi.org\/10.1016\/j.ctrv.2016.04.004.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2983_CR23","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/1078-0432.CCR-04-1946","volume":"11","author":"T Suganuma","year":"2005","unstructured":"Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res. 2005;11(7):2686\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1946.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2983_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ygyno.2014.06.031","volume":"135","author":"YA Park","year":"2014","unstructured":"Park YA, Choi CH, Do IG, Song SY, Lee JK, Cho YJ, et al. Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma. Gynecol Oncol. 2014;135(1):108\u201317. https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.031.","journal-title":"Gynecol Oncol"},{"key":"2983_CR25","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.2147\/OTT.S167422","volume":"11","author":"Z Na","year":"2018","unstructured":"Na Z, Qiao X, Hao X, Fan L, Xiao Y, Shao Y, et al. The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients. Onco Targets Ther. 2018;11:4913\u201344. https:\/\/doi.org\/10.2147\/OTT.S167422.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2983_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","volume":"121","author":"A Yap","year":"2018","unstructured":"Yap A, Lopez-Olivo MA, Dubowitz J, Pratt G, Hiller J, Gottumukkala V, et al. Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies. Br J Anaesth. 2018;121(1):45\u201357. https:\/\/doi.org\/10.1016\/j.bja.2018.03.024.","journal-title":"Br J Anaesth"},{"issue":"6","key":"2983_CR27","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.3802\/jgo.2018.29.e82","volume":"29","author":"MH Baek","year":"2018","unstructured":"Baek MH, Kim DY, Kim SO, Kim YJ, Park YH. Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study. J Gynecol Oncol. 2018;29(6):e82. https:\/\/doi.org\/10.3802\/jgo.2018.29.e82.","journal-title":"J Gynecol Oncol"},{"issue":"5","key":"2983_CR28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18(5):1201\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0641.","journal-title":"Clin Cancer Res"},{"key":"2983_CR29","unstructured":"Lisauskien\u0117 I. Changes in Cardiovascular Medicines Utilization and Morbidity and Mortality from Cardiovascular Disease in Lithuania. Doctoral Dissertation. Vilnius:Vilnius University; 2017. 110 p."},{"issue":"10","key":"2983_CR30","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00228-022-03369-0","volume":"78","author":"I Treciokiene","year":"2022","unstructured":"Treciokiene I, Bratcikoviene N, Gulbinovic J, Wettermark B, Taxis K. Non-persistence to antihypertensive drug therapy in Lithuania. Eur J Clin Pharmacol. 2022;78(10):1687\u201396. https:\/\/doi.org\/10.1007\/s00228-022-03369-0.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2983_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10552-019-01157-3","volume":"30","author":"AN Minlikeeva","year":"2019","unstructured":"Minlikeeva AN, Cannioto R, Jensen A, Kjaer SK, Jordan SJ, Diergaarde B, et al. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes Control. 2019;30(5):537\u201347.","journal-title":"Cancer Causes Control"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-02983-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-024-02983-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-02983-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:05:11Z","timestamp":1709928311000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-024-02983-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2983"],"URL":"https:\/\/doi.org\/10.1186\/s12905-024-02983-7","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"5 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the research has been obtained from the Vilnius Regional Biomedical Research Ethics Committee (reference number: 2021\/3-1322-798). The Vilnius Regional Biomedical Research Ethics Committee waived the need to obtain informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}